YWYirong Wu

Yirong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yirong Wu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Zhengyun Zou

    Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China

    2 shared publications
  • Donglin Kang

    Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China

    1 shared publication
  • Jiayu Wang

    Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China

    1 shared publication
  • Lianjun Zhao

    Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu Province, China

    1 shared publication
  • Lin Li

    Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    1 shared publication
  • Qi Sun

    Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Characteristics of cancer mycobiome in patients with acral melanoma

    by Rong Huang, Xinyu Su, Jiayu Wang, Qi Sun, Donglin Kang, Lin Li, Yirong Wu, Lianjun Zhao, Ziyao Xie, Zhengyun Zou

    Background: Intratumoral fungi have recently been implicated in cancer initiation and progression, with potential as biomarkers for predicting clinical outcomes and treatment response in patients with cancer. However, their role in acral melanoma (AM) has not been previously explored. Methods: We characterized the mycobiome in AM tumor tissues and adjacent non-tumor tissues. Differences in fungal communities between the two tissues, as well as the prognostic and diagnostic potential of intratumoral fungi, and their associations with the tumor microenvironment and clinicopathologic features, were evaluated through bioinformatics and biostatistical analyses. Results: Although some intratumoral fungi originated from adjacent tissues, AM tumors exhibited a distinct fungal composition characterized by altered species richness, community structure, and an increased Ascomycota-to-Basidiomycota ratio. Several fungal taxa were identified as potential diagnostic and prognostic biomarkers and showed significant correlations with clinical parameters and immune infiltration. Specifically, the CD68-high samples harbored greater fungal diversity and higher relative abundance of Endocarpon compared with CD68-low samples. Furthermore, fungi–bacteria interactions were characterized by significant negative correlations between their diversity, while positive interspecies interactions dominated the network. Conclusions: These findings underscore the potential role of the cancer mycobiome in AM and offer new insights into the tumor microenvironment and its implications for cancer prevention and therapy.


  • Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects

    by Rong Huang, Yirong Wu, Zhengyun Zou

    EZH2 is an epigenetic regulator that methylates lysine 27 on histone H3 (H3K27) and is closely related to the development and metastasis of tumors. It often shows gain-of-function mutations in hema... Plain language summary EZH2 is a histone methyltransferase whose high expression is associated with a poor prognosis in various solid tumors. It is considered a target for cancer treatment. However... Tweetable abstract Review describing EZH2 inhibitors combined with other antitumor therapy to provide therapeutic synergy for solid tumor treatment.